The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 1 - 10 of 15
Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative findings on MPT attribute preferences from the CUPID study (MTN-045)
This article from the Journal of the International AIDS Society uses data from the Microbicide Trials Network 045 study in Uganda and Zimbabwe to examine (1) how couples make decisions on existing non-Multipurpose Technology (MPT) HIV and pregnancy prevention products; (2) how couples make decisions on future ideal-MPT products; and (3) how these decision-making processes…
Demand Creation/Marketing, Research
Results of 90 Day Tenofovir plus Levonorgestrel Vaginal Ring Trial: The CONRAD 138 study
This article from PLOS One presents the results of a randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics, and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women to prevent both pregnancy and HIV.
DPP Audience & Provider Insights for the DPP Research and Marketing Plan: Phase 1 Research Findings
This report, by M&C Saatchi World Services, AVAC, and partners, highlights learnings from Human-Centered Design Research undertaken in 2022 to understand the values and motivations of potential users and influencers of the Dual Prevention Pill (DPP) in Kenya, South Africa, and Zimbabwe.
Private sector delivery opportunities for the Dual Prevention Pill: Lessons from Family Planning for the introduction of Multi-purpose Prevention Technologies
Recording / Slides / Notes Please join AVAC and FP2030 for a webinar on the DPP, a daily pill that is currently being developed for simultaneous pregnancy and HIV prevention. This webinar will highlight new findings on private sector opportunities for the DPP in Kenya, South Africa and Zimbabwe. It will explore lessons and successes…
Dual Prevention Pill Desk Review Insights
This desk review by M&C Saatchi collates existing data and insights related to uptake and adherence to HIV prevention, contraceptive, and multi-purpose technology pill products; confirms and identifies gaps in the existing knowledge base; and prompts discussions around key learning questions that need to be addressed to develop a robust and effective marketing and demand…
Review of Effective Marketing and Demand Creation Strategies in HIV Prevention and Family Planning that May Inform Demand-Side Thinking for the Dual Prevention Pill
This scoping review aims to document effective and sustainable demand creation strategies used in HIV prevention and Family Planning interventions, how they may be adapted for the Dual Prevention Pill (DPP), and explores what could be done differently for the DPP.
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through 2024.
IAS 2021 Satellite Session: Bringing the Dual Prevention Pill to Market: Opportunities for HIV and Pregnancy Prevention and Implications for Future MPTs
This video-recorded session from IAS 2021 examines opportunities for bringing the Dual Prevention Pill to market as well as implications for future multipurpose prevention technologies.
The Future of ARV-Based Prevention and More
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
Developing and Introducing a Dual Prevention Pill- Oral PrEP & oral contraception for HIV and pregnancy prevention
A coalition of partners is developing a novel Dual Prevention Pill (DPP) for prevention of pregnancy and HIV acquisition in high-need countries. In East and Southern Africa — where the DPP is initially planned for introduction — 65 percent of new HIV infections are amongst women aged 15 and over, and 16 percent of women…